Torrent Pharmaceuticals’ shares opened slightly lower on September 27 after the Central Drug Standards Control Organisation (CDSCO) reported that Shelcal 500, one of its popular calcium supplements, failed a quality test.
Torrent Pharma refuted the findings, asserting that they did not manufacture the batch of Shelcal 500 flagged by CDSCO and is “spurious.” The company emphasized that it has implemented QR codes for batch verification, which were absent in the seized samples. Torrent has submitted its evaluation report to CDSCO, concluding that the drug in question was not genuine.
At 9:15 am, Torrent Pharma shares were trading at Rs 3,396 on the NSE, down by 0.4 percent.
This comes after CDSCO reported over 50 drugs as “not of standard quality” in recent tests, sparking concerns about drug safety in the Indian market.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com
Source: Moneycontrol
News Desk
